Open Access

Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

  • Authors:
    • Shigeo Shimose
    • Takumi Kawaguchi
    • Masatoshi Tanaka
    • Hideki Iwamoto
    • Ken Miyazaki
    • Etsuko Moriyama
    • Hiroyuki Suzuki
    • Takashi Niizeki
    • Tomotake Shirono
    • Masahito Nakano
    • Hideya Suga
    • Taizo Yamaguchi
    • Yoshinori Yokokura
    • Kazunori Noguchi
    • Hironori Koga
    • Takuji Torimura
  • View Affiliations

  • Published online on: June 19, 2020     https://doi.org/10.3892/ol.2020.11758
  • Pages: 2257-2265
  • Copyright: © Shimose et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tyrosine kinase inhibitors are considered for use in patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE). The aim of the present retrospective study was to identify factors associated with progression‑free survival (PFS) and to evaluate the indications for lenvatinib treatment in patients with intermediate‑stage HCC refractory to TACE using a data‑mining analysis. A total of 171 patients with intermediate‑stage HCC refractory to TACE were included. All patients were classified into three groups according to their HCC treatment: Lenvatinib (n=45), sorafenib (n=53) and TACE (n=73) groups. PFS time was calculated using the Kaplan‑Meier method and analyzed using a log‑rank test. Factors associated with PFS time were evaluated using multivariate and decision‑tree analyses. The median PFS time was 5.8, 3.2 and 2.4 months in the lenvatinib, sorafenib and TACE groups, respectively (P<0.001). In the Cox regression analysis, lenvatinib treatment and being within the up‑to‑seven criteria were identified as independent factors for PFS (lenvatinib, P<0.0001; within up‑to‑seven, P=0.001). The decision‑tree analysis revealed that patients beyond the up‑to‑seven criteria, treated with lenvatinib and with albumin‑bilirubin (ALBI) grade 1 had a longer PFS time (245.2±107.9 days) than patients beyond the up‑to‑seven criteria, treated with lenvatinib and with ALBI grade 2 (147.1±78.6 days). Additionally, lenvatinib was independently associated with longer PFS time in patients with intermediate‑stage HCC refractory to TACE. Therefore, lenvatinib may be recommended for patients who have intermediate‑stage HCC refractory to TACE, ALBI grade 1 and who are within the up‑to‑seven criteria.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Nakano M, et al: Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett 20: 2257-2265, 2020
APA
Shimose, S., Kawaguchi, T., Tanaka, M., Iwamoto, H., Miyazaki, K., Moriyama, E. ... Torimura, T. (2020). Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncology Letters, 20, 2257-2265. https://doi.org/10.3892/ol.2020.11758
MLA
Shimose, S., Kawaguchi, T., Tanaka, M., Iwamoto, H., Miyazaki, K., Moriyama, E., Suzuki, H., Niizeki, T., Shirono, T., Nakano, M., Suga, H., Yamaguchi, T., Yokokura, Y., Noguchi, K., Koga, H., Torimura, T."Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis". Oncology Letters 20.3 (2020): 2257-2265.
Chicago
Shimose, S., Kawaguchi, T., Tanaka, M., Iwamoto, H., Miyazaki, K., Moriyama, E., Suzuki, H., Niizeki, T., Shirono, T., Nakano, M., Suga, H., Yamaguchi, T., Yokokura, Y., Noguchi, K., Koga, H., Torimura, T."Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis". Oncology Letters 20, no. 3 (2020): 2257-2265. https://doi.org/10.3892/ol.2020.11758